Log In
BCIQ
Print this Print this
 

ONC-392

  Manage Alerts
Collapse Summary General Information
Company OncoImmune Inc.
DescriptionMAb against cytotoxic T-lymphocyte associated protein 4 (CTLA4; CD152)
Molecular Target Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$250.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/15/2016

$250.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today